Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...

Novartis (NVS) stock traded lower after Bank of America downgraded the Swiss drugmaker to neutral, citing a cautious outlook ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...